Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The In¯Uence of Medication on Erectile Function
International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
(19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes. -
(12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb. -
A Systematic Review of Combination and High-Dose Atypical
APPENDIX 12: STUDY CHARACTERISTICS OF INCLUDED STUDIES Number of Interventions/ Adjunctive Treatment APDs Failed Sample Author, Year Country Sponsor Comparators Medications Duration Prior to Size (Mean Dose) Allowed (Weeks) Study Grant from Stanley Medical research Institute, RIS+CLZ Benzodiazepines Janssen 515.6±138.7 mg/d CLZ for anxiety and/or AKDEDE et al. Pharmaceutica, and 42 Turkey biperiden for 6 weeks ≥3 30 (2005) THE Ritter 5.1±1.3 mg/day RIS EPS allowed if Foundation, the PLC+CLZ necessary William K. 414.3±96.9 mg/d CLZ Warren Medical Research Foundation ANIL YAGCIOGLU et 45 See Akdede 2006 al. (2005) AMI400+CLZ 400mg/d AMI and 300 Occasional mg/d CLZ intake of 49 Sanofi- AMI600+CLZ benzodiazepines, ASSION et al. (2008) Germany 6 weeks ≥1 16 Synthelabo 600 mg/d AMI and sedatives, or 300mg/d CLZ antidepressants PLC+CLZ allowed 300 mg/d CLZ 60 France and Novartis Phama RIS (H): median 9 mg/d AZORIN et al. (2001) Not reported 12 weeks ≥1 273 Canada S.A. CLZ: median: 600 mg/d Lorazepam or Janssen oxazepam for BONDOLFI et al. France and RIS (H): 6.4 mg/d 66 Research sleep induction 8 weeks ≥2 86 (1998) Switzerland CLZ: 291.2 mg/d Foundation or daytime sedation; 156 Systematic Review of Combination and High-Dose AAPs for Schizophrenia Number of Interventions/ Adjunctive Treatment APDs Failed Sample Author, Year Country Sponsor Comparators Medications Duration Prior to Size (Mean Dose) Allowed (Weeks) Study biperiden and procyclidine for EPS Supported by grants from Brain Research center, funded by the ARI+CLZ Antidepressants, Ministry of 15.5±7.1 mg/d ARI and 38 anticholinergics CHANG et al. -
Partial Agreement in the Social and Public Health Field
COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this -
Monoamine Reuptake Inhibitors in Parkinson's Disease
Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters. -
Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey I
Downloaded from jpet.aspetjournals.org at ASPET Journals on October 1, 2021 NV PH JPET #247171 i HA,PH 1 Adjia Hamadjida, Philippe Huot Adjia Philippe Hamadjida, , JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Psychiatric Effects of Drugs for Other Disorders
TREATMENT STRATEGIES Psychiatric effects of drugs What’s new? for other disorders • Rimonabant, a cannabinoid CB1 receptor antagonist, is effective for weight loss in obesity but carries a 2.5-fold risk C Heather Ashton of depression and a threefold risk of anxiety compared with placebo • Nabilone, a synthetic cannabinoid receptor agonist similar to tetrahydrocannabinol (THC), and sativex, a plant- derived agent containing THC and cannabidiol, alleviate pain in spastic disorders and neuropathic pain; psychiatric Abstract side-effects are minimized by using modest doses and/or Many drugs used therapeutically for non-psychiatric disorders can cause combination with opioids or other analgesics neuropsychiatric reactions. A wide range of such effects are reported including sedation, sleep disturbance, anxiety, depression, mania, psy- • Abrupt withdrawal of baclofen may cause serious psychiatric chosis, cognitive disturbance and delirium. The reactions are usually reactions, especially delirium, and after chronic use the drug dose-related but may occur at therapeutic doses or on drug withdrawal should be withdrawn gradually over several weeks after chronic use. They are more common in elderly or ill patients or those with a psychiatric history and may be unpredictable or paradoxi- • Isotretinoin has not been shown to increase the risk of cal. Some of the more common psychiatric effects of drugs used for depression or suicide in adolescents treated for severe acne non-psychiatric disorders are reviewed briefly here. They include, among but remains under suspicion of causing rare paradoxical others, dopaminergic and antimuscarinic drugs for parkinsonism; digi- reactions talis and β-adrenoceptor antagonists for cardiovascular disorders; can- nabinoid receptor antagonists for obesity; corticosteroids for endocrine disorders, asthma and allergic conditions; and anti-infective drugs for bacterial, parastic and viral infections. -
Acute Laryngeal Dystonia
Collins N, Sager J. J Neurol Neuromedicine (2018) 3(1): 4-7 Neuromedicine www.jneurology.com www.jneurology.com Journal of Neurology & Neuromedicine Mini Review Open Access Acute laryngeal dystonia: drug-induced respiratory failure related to antipsychotic medications Nathan Collins*, Jeffrey Sager Santa Barbara Cottage Hospital Department of Internal Medicine Santa Barbara, CA, USA Article Info ABSTRACT Article Notes Acute laryngeal dystonia (ALD) is a drug-induced dystonic reaction that can Received: December 10, 2017 lead to acute respiratory failure and is potentially life-threatening if unrecognized. Accepted: January 16, 2018 It was first reported in 1978 when two individuals were noticed to develop *Correspondence: difficulty breathing after administration of haloperidol. Multiple cases have since Dr. Nathan Collins MD been reported with the use of first generation antipsychotics (FGAs) and more Santa Barbara Cottage Hospital recently second-generation antipsychotics (SGAs). Acute dystonic reactions (ADRs) Department of Internal Medicine, Santa Barbara, CA, USA, have an occurrence rate of 3%-10%, but may occur more frequently with high Email: [email protected] potency antipsychotics. Younger age and male sex appear to be the most common risk factors, although a variety of metabolic abnormalities and illnesses have also © 2018 Collins N. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License been associated with ALD as well. The diagnosis of ALD can go unrecognized as other causes of acute respiratory failure are often explored prior to ALD. The exact mechanism for ALD remains unclear, yet evidence has shown a strong correlation with extrapyramidal symptoms (EPS) and dopamine receptor blockade. -
Review Article Monoamine Reuptake Inhibitors in Parkinson's Disease
Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review